Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page
Price
Target price
€108.20

€108.20

-2.350%
-2.75
-2.350%
€129.45

€129.45

 
Latest predictions
-
07.08.20
€130.00
06.08.20
buy
€135.00
20.07.20
buy
€130.00
15.07.20
buy
-
11.07.20
buy
€130.00
06.06.20
buy
Your prediction

Morphosys AG Stock

We can see a decrease in the price for Morphosys AG. Compared to yesterday it has lost -€2.750 (-2.350%).
With 17 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of €129.00 there is a slightly positive potential of 19.224% for Morphosys AG compared to the current price of €108.20.

Pros and Cons of Morphosys AG in the next few years

Pros
?
Conscious of the environment
?
Brand
?
Growth compared to competition
Cons
?
Non-cyclic/Cyclic
?
Market Position
?
Future proof business model
Tell us your opinion to access the 'Wisdom of the Crowds'

Comments

Buy Morphosys AG

Buy Morphosys AG

Buy Morphosys AG

Show more
You may not comment on this article as you either did not confirm your account yet or were blocked. If you think this is a mistake please contact us. Show more

Other discussions about Morphosys AG Stock

Trading Morphosys AG

Trading Morphosys AG

New thread Forum

News

DGAP-News: MorphoSys Reports Second Quarter and First Half 2020 Results: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys Reports Second Quarter and First Half 2020 Results

DGAP-News: MorphoSys Reports Second Quarter and First Half 2020 Results

DGAP-Adhoc: MorphoSys AG: Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-Adhoc: MorphoSys AG: Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

DGAP-Adhoc: MorphoSys AG: Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

DGAP-News: Invitation to MorphoSys' Second Quarter and First Half 2020 Results Conference Call on August 6, 2020: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: Invitation to MorphoSys' Second Quarter and First Half 2020 Results Conference Call on August 6, 2020

DGAP-News: Invitation to MorphoSys' Second Quarter and First Half 2020 Results Conference Call on August 6, 2020

DGAP-News: MororphoSys's Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MororphoSys's Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis

DGAP-News: MororphoSys's Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis

DGAP-News: MorphoSys to Present at Upcoming Virtual Investor Conferences: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys to Present at Upcoming Virtual Investor Conferences

DGAP-News: MorphoSys to Present at Upcoming Virtual Investor Conferences

DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2020: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2020

DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2020

DGAP-News: MorphoSys and Incyte Announce the Validation of the European Marketing Authorization Application for Tafasitamab: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys and Incyte Announce the Validation of the European Marketing Authorization Application for Tafasitamab

DGAP-News: MorphoSys and Incyte Announce the Validation of the European Marketing Authorization Application for Tafasitamab

DGAP-News: MorphoSys to Present Data on Tafasitamab at the ASCO and EHA Virtual Meetings: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys to Present Data on Tafasitamab at the ASCO and EHA Virtual Meetings

DGAP-News: MorphoSys to Present Data on Tafasitamab at the ASCO and EHA Virtual Meetings

DGAP-News: MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r/r DLBCL: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r/r DLBCL

DGAP-News: MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r/r DLBCL

DGAP-News: MorphoSys Reports First Quarter 2020 Results: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys Reports First Quarter 2020 Results

DGAP-News: MorphoSys Reports First Quarter 2020 Results

DGAP-News: Invitation to MorphoSys' First Quarter 2020 Results Conference Call on May 7, 2020: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: Invitation to MorphoSys' First Quarter 2020 Results Conference Call on May 7, 2020

DGAP-News: Invitation to MorphoSys' First Quarter 2020 Results Conference Call on May 7, 2020

DGAP-News: MorphoSys and I-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202/TJ202 in r/r Multiple Myeloma in Mainland ChinaMorphoSys AG: : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys and I-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202/TJ202 in r/r Multiple Myeloma in Mainland ChinaMorphoSys AG:

DGAP-News: MorphoSys and I-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202/TJ202 in r/r Multiple Myeloma in Mainland ChinaMorphoSys AG:

DGAP-News:  MorphoSys Appoints Roland Wandeler, Ph.D., as Chief Commercial Officer: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys Appoints Roland Wandeler, Ph.D., as Chief Commercial Officer

DGAP-News: MorphoSys Appoints Roland Wandeler, Ph.D., as Chief Commercial Officer

DGAP-News: MorphoSys Provides Update on Impact of COVID-19 on Business Operations and Precautionary Measures: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys Provides Update on Impact of COVID-19 on Business Operations and Precautionary Measures

DGAP-News: MorphoSys Provides Update on Impact of COVID-19 on Business Operations and Precautionary Measures

DGAP-News: MorphoSys Presents Results for Fiscal Year 2019: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys Presents Results for Fiscal Year 2019

DGAP-News: MorphoSys Presents Results for Fiscal Year 2019

DGAP-News: Invitation to MorphoSys' Year-End Results 2019 Conference Call on March 19, 2020: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: Invitation to MorphoSys' Year-End Results 2019 Conference Call on March 19, 2020

DGAP-News: Invitation to MorphoSys' Year-End Results 2019 Conference Call on March 19, 2020

DGAP-News: MorphoSys Resolves a Capital Increase to Implement the Purchase of 3,629,764 American Depositary Shares by Incyte Corporation: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys Resolves a Capital Increase to Implement the Purchase of 3,629,764 American Depositary Shares by Incyte Corporation

DGAP-News: MorphoSys Resolves a Capital Increase to Implement the Purchase of 3,629,764 American Depositary Shares by Incyte Corporation

DGAP-News: MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab

DGAP-News: MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab

DGAP-News: FDA Accepts MorphoSys' Biologics License Application (BLA) and Grants Priority Review for Tafasitamab and Lenalidomide for the Treatment of Relapsed/Refractory DLBCL : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: FDA Accepts MorphoSys' Biologics License Application (BLA) and Grants Priority Review for Tafasitamab and Lenalidomide for the Treatment of Relapsed/Refractory DLBCL

DGAP-News: FDA Accepts MorphoSys' Biologics License Application (BLA) and Grants Priority Review for Tafasitamab and Lenalidomide for the Treatment of Relapsed/Refractory DLBCL